BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 11960075)

  • 1. Rosiglitazone-induced granulomatous hepatitis.
    Dhawan M; Agrawal R; Ravi J; Gulati S; Silverman J; Nathan G; Raab S; Brodmerkel G
    J Clin Gastroenterol; 2002; 34(5):582-4. PubMed ID: 11960075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe cholestatic hepatitis caused by thiazolidinediones: risks associated with substituting rosiglitazone for troglitazone.
    Bonkovsky HL; Azar R; Bird S; Szabo G; Banner B
    Dig Dis Sci; 2002 Jul; 47(7):1632-7. PubMed ID: 12141828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver failure in a patient treated with long-term rosiglitazone therapy.
    Gouda HE; Khan A; Schwartz J; Cohen RI
    Am J Med; 2001 Nov; 111(7):584-5. PubMed ID: 11705443
    [No Abstract]   [Full Text] [Related]  

  • 4. Hepatocellular injury in a patient receiving rosiglitazone. A case report.
    Al-Salman J; Arjomand H; Kemp DG; Mittal M
    Ann Intern Med; 2000 Jan; 132(2):121-4. PubMed ID: 10644273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction.
    Lebovitz HE; Kreider M; Freed MI
    Diabetes Care; 2002 May; 25(5):815-21. PubMed ID: 11978674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correction: Liver injury and rosiglitazone.
    Ann Intern Med; 2000 Aug; 133(3):237. PubMed ID: 10906846
    [No Abstract]   [Full Text] [Related]  

  • 7. Hepatic injury due to troglitazone.
    Malik AH; Prasad P; Saboorian MH; Thiele DL; Malet PF
    Dig Dis Sci; 2000 Jan; 45(1):210-4. PubMed ID: 10695637
    [No Abstract]   [Full Text] [Related]  

  • 8. Hepatotoxicity of the thiazolidinediones.
    Tolman KG; Chandramouli J
    Clin Liver Dis; 2003 May; 7(2):369-79, vi. PubMed ID: 12879989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Granulomatous hepatitis associated with glyburide.
    Saw D; Pitman E; Maung M; Savasatit P; Wasserman D; Yeung CK
    Dig Dis Sci; 1996 Feb; 41(2):322-5. PubMed ID: 8601376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rosiglitazone toxicity.
    Ravinuthala RS; Nori U
    Ann Intern Med; 2000 Oct; 133(8):658. PubMed ID: 11033603
    [No Abstract]   [Full Text] [Related]  

  • 11. Thiazolidinedione hepatotoxicity: a class effect?
    Tolman KG
    Int J Clin Pract Suppl; 2000 Oct; (113):29-34. PubMed ID: 11965828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatotoxicity with thiazolidinediones: is it a class effect?
    Scheen AJ
    Drug Saf; 2001; 24(12):873-88. PubMed ID: 11735645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isolated elevation of alkaline phosphatase level associated with rosiglitazone.
    Hachey DM; O'Neil MP; Force RW
    Ann Intern Med; 2000 Nov; 133(9):752. PubMed ID: 11074926
    [No Abstract]   [Full Text] [Related]  

  • 14. Failure to develop hepatic injury from rosiglitazone in a patient with a history of troglitazone-induced hepatitis.
    Lenhard MJ; Funk WB
    Diabetes Care; 2001 Jan; 24(1):168-9. PubMed ID: 11194222
    [No Abstract]   [Full Text] [Related]  

  • 15. Thiazolidinediones for type 2 diabetes. New agents reduce insulin resistance but need long term clinical trials.
    Krentz AJ; Bailey CJ; Melander A
    BMJ; 2000 Jul; 321(7256):252-3. PubMed ID: 10915108
    [No Abstract]   [Full Text] [Related]  

  • 16. Thiazolidinediones in diabetes: current status and future outlook.
    Camp HS
    Curr Opin Investig Drugs; 2003 Apr; 4(4):406-11. PubMed ID: 12808879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe but reversible hepatitis induced by troglitazone.
    Schiano T; Dolehide K; Hart J; Baker AL
    Dig Dis Sci; 2000 May; 45(5):1039-42. PubMed ID: 10795774
    [No Abstract]   [Full Text] [Related]  

  • 18. Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy.
    May LD; Lefkowitch JH; Kram MT; Rubin DE
    Ann Intern Med; 2002 Mar; 136(6):449-52. PubMed ID: 11900497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Meta-analysis shows: insulin sensitizer is safe for the liver].
    MMW Fortschr Med; 2002 Oct; 144(40):47. PubMed ID: 12440297
    [No Abstract]   [Full Text] [Related]  

  • 20. [Severe electrolyte imbalance and edema in therapy with rosiglitazone].
    Kuschel U; Hesselbarth N; Herrmann A; Hippius M; Hoffmann A
    Med Klin (Munich); 2002 Sep; 97(9):553-5. PubMed ID: 12371084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.